UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 910, 2010

QuadraMed Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-32283

52-1992861

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

12110 Sunset Hills Road, Suite 600, Reston, VA 20190

(Address of principal executive office and zip code)

(703) 709-2300

(Registrant’s telephone number, including area code)

(Not Applicable)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

ITEM 5.07	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS	2
ITEM 5.02	DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY AGREEMENTS OF CERTAIN OFFICERS.	3
ITEM 8.01	OTHER EVENTS	2
SIGNATURES		4
SIGNATURES		3
EXHIBIT INDEX		3
EXHIBIT 99.1	PRESS RELEASE BY QUADRAMED CORPORATION DATED MARCH 9, 2010
EXHIBIT 99.2	PRESS RELEASE BY QUADRAMED CORPORATION DATED MARCH 9, 2010

ITEM 5.0702 ~~SUBMISSION~~Departure OFof ~~MATTERS~~Directors TOor APrincipal ~~VOTE~~Officers; OFElection ~~SECURITY~~of ~~HOLDERS~~Directors; Appointment of Certain Officers; Compensatory Agreements of Certain Officers.

~~Results~~On March 10, 2010, David L. Piazza, the Executive Vice President, Chief Financial Officer and Chief Operating Officer of ~~Special~~QuadraMed ~~Meeting~~Corporation (the “Company”), received a discretionary bonus in the amount of ~~Stockholders~~$45,000 in recognition of his 2009 performance. Such bonus was granted by and at the discretion of Duncan W. James, the Company’s President and Chief Executive Officer, based on the authorization given by the Compensation Committee of the Company’s Board of Directors to Mr. James to make discretionary bonus awards to Company personnel from a supplemental bonus pool. Such bonus was paid at the time of the Company’s payments to personnel in respect of the targets achieved under the 2009 Incentive Compensation Plan (the “2009 ICP”). A copy of the 2009 ICP was filed with the Commission on the Company’s Current Report on Form 8-K on May 5, 2009.

(a) At 12:00 p.m. on March 9, 2010, QuadraMed Corporation, a Delaware corporation (“QuadraMed” or the “Company”) held a special meeting of its stockholders at the Hyatt Dulles, located at 2300 Dulles Corner Blvd., Herndon, Virginia 20171 (the “Special Meeting”).

(b) The issued and outstanding shares of stock of the Company entitled to vote at the Special Meeting consisted of 8,307,939 shares of common stock. The common stockholders of the Company voted on two matters at the Special Meeting, both of which were approved pursuant to the following final voting results from the Special Meeting:

(1) A proposal to adopt the Agreement and Plan of Merger, as it may be amended from time to time (the “Merger Agreement”), dated as of December 7, 2009, by and among QuadraMed, Bavaria Holdings Inc., a Delaware corporation controlled by Francisco Partners (the “Parent”) and Bavaria Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Parent (“Merger Sub”), and to approve the Parent’s acquisition of QuadraMed through a merger of Merger Sub with and into QuadraMed, with QuadraMed surviving the merger as a wholly owned subsidiary of the Parent, as contemplated by the Merger Agreement.

FOR		AGAINST		ABSTAIN
6,532,119		231,221		2,526

(2) A proposal to approve any adjournments of the Special Meeting to a later date or time, if necessary, to permit further solicitation of proxies if there are insufficient votes at the time of the Special Meeting, or at any adjournment or postponement thereof, to adopt the Merger Agreement and approve the merger.

FOR		AGAINST		ABSTAIN
6,464,174		299,403		2,289

ITEM 8.01 OTHER EVENTS.

On March 9, 2010, QuadraMed Corporation issued two press releases attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, both incorporated into this Item 8.01 by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit 99.1		Press release issued by QuadraMed Corporation dated March 9, 2010.
Exhibit 99.2		Press release issued by QuadraMed Corporation dated March 9, 2010.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 1016, 2010

QuadraMed Corporation /s/ ~~David~~Duncan LW. ~~Piazza~~James ~~David~~Duncan LW. ~~Piazza,~~James ~~Executive Vice~~ President, ~~Chief Financial Officer~~ and Chief ~~Operating~~Executive Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Press release issued by QuadraMed Corporation dated March 9, 2010
99.2		Press release issued by QuadraMed Corporation dated March 9, 2010

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · QUADRAMED CORP